Bradley Pharmaceuticals, Inc. (NYSE: BDY) announced today that the Company has been notified by BioSante Pharmaceuticals (Amex: BPA) that they received approval from the Food and Drug Administration to market Elestrin(TM) (formerly called Bio-E-Gel(R)), BioSante's estradiol transdermal gel indicated for the treatment of moderate to severe hot flashes in menopausal women. Elestrin(TM) will be the lowest effective dose of estradiol available and will conform to the recommendations directed to physicians by the FDA and the American College of Obstetricians and Gynecologists (ACOG) to prescribe the lowest effective dose of estrogen to control menopausal symptoms such as hot flashes. An issued patent covers gel formulations into 2017, and pending patents, if issued, will protect the Elestrin(TM)...